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ABSTRACT
Background    Fucoidan is a high-molecular polysac-
charide whose main constituent is sulfated fucose. We 
specifically focused on the anti-proliferation activity of 
fucoidan and examined the underlying mechanism in 
MKN45 gastric cancer cells.  
Methods    MKN45 cell proliferation was analyzed by 
BrdU assay and fucoidan cytotoxicity was examined by 
LDH and clonogenic assays. The Agilent Human micro-
array kit was used to identify upregulated and downreg-
ulated genes in response to fucoidan, and western blot 
analyses evaluated cell cycle proteins. 
Results    Fucoidan impeded the MKN45 cell cycle 
by approximately 50%, and inhibited cell prolifera-
tion. LDH assays showed no immediate cytotoxic ef-
fects of fucoidan at 24 h exposure, however longer time 
courses revealed cell growth inhibition at 4 days in a 
dose-dependent manner. Microarray analysis identified 
MAP3K5, or ASK1 (apoptosis signal-regulating kinase), 
which was upregulated by 1.38-fold upon fucoidan treat-
ment. Fucoidan increased ASK1 protein levels, while re-
ducing phosphorylated ASK1 levels. Reduction of ASK1 
by siRNA decreased proliferation of MKN45 cells. 
Conclusion    Our findings show that fucoidan may 
suppress cellular proliferation and DNA synthesis in 
MKN45 cells by suppressing the ASK1-p38 signaling 
pathway through reduction of phosphorylated ASK1 lev-
els. 
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Fucoidan is a high-molecular polysaccharide only found 
in brown algae and its main constituent is sulfated fu-
cose. The saccharide chain also includes galactose, man-
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nose, xylose and uronic acid. Over the past decades, fu-
coidan has been extensively studied, owing to its numer-
ous interesting biological activities, such as antioxidant,1 
immunomodulatory,2 antiviral,3 antithrombotic4 and 
anticoagulant effects.5 In particular, we have focused on 
the anti-cancer activities of fucoidan. 
 Multiple studies have demonstrated antitumor activ-
ity for many polysaccharides. Fucoidans from Eisenia 
bicyclis and Laminaria japonica are effective against 
sarcoma 180.6, 7 Fucoidan from L. japonica can inhibit 
hepatoma QGY7703 cell growth in logarithmic phase in 
vitro, thus restraining the growth of tumors.8 Fucoidans 
from L. saccharina, L. digitata, Fucus serratus, F. disti-
chus and F. vesiculosus strongly blocked MDA-MB-231 
breast carcinoma cell adhesion to platelets, an effect that 
might have critical implications in tumor metastasis.9
 Among its various anti-cancer effects, we have 
focused on the antiproliferation activities of fucoidan. 
We hypothesized that fucoidan exerts its anti-cancer 
effects through alterations of gene expression. Thus, in 
this study, we performed mRNA microarray analysis to 
examine the effects of fucoidan on cellular gene expres-
sion. We selected MKN45 gastric cancer cells for analy-
sis, as this common cancer cell line is relatively easy to 
culture and is often used for experimental analyses.10–12
 
MATERIALS AND METHODS
Reagents
The human gastric adenocarcinoma cell line, MKN45 
was obtained from the Riken BioResource Center 
(National Bio-Resource Project of the Ministry of 
Education, Culture, Sports, Science and Technology, 
Tsukuba, Japan) in November 20, 2012. Cells were 
maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS). MKN45 gastric adenocarcinoma 
cells were obtained from a metastatic liver tumor in a 
62-year-old Japanese female.
 Dulbecco’s modified Eagle medium (DMEM), 
trypsin-EDTA, and the lactate dehydrogenase (LDH) 
assay kit were obtained from Wako (Tokyo, Japan). 
FBS was from Biowest (Nuaillé, France). Rabbit poly-
clonal anti-ASK1 (H-300), anti-ERK1 (K-23), mouse 
monoclonal anti-phospho-ERK (E-4), and ASK1 siRNA 
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were purchased from Santa Cruz Biotech (Santa Cruz, 
CA). Rabbit polyclonal anti-phospho-ASK1 (Thr845), 
rabbit monoclonal anti-p38 MAPK (D13E1) and anti-
phospho-p38 MAPK (Thr180/Tyr182) (D3F9) were from 
Cell Signaling Technology (Danvers, MA). Horserad-
ish peroxidase-conjugated anti-rabbit immunoglobulin 
(IgG), anti-mouse IgG, and the ECL plus detection kit 
were from GE Healthcare (Buckinghamshire, United 
Kingdom). Alexa Fluor 488-conjugated anti-rabbit IgG 
was from Invitrogen (Carlsbad, CA). 
Preparation of fucoidan
High molecular weight fucoidan was obtained from 
Marine Products Kimuraya (Sakaiminato, Japan) as a 
sulfated polysaccharide, extracted from the brown sea-
weed Cladosiphon okamuranus (Okinawa Mozuku) as 
previously described.13, 14 The mean molecular weight 
was 4 × 105 and the active ingredient contained 14.2% 
sulfate (SO42−). The material has been previously used in 
studies on biological activity and with respect to safety 
of human use.15–17
Cell culture, cell growth and cell death assay
Cells were cultured in DMEM with 10% FBS. For fucoi-
dan treatment, culture medium was replaced with fresh 
medium mixed with indicated concentrations of fucoi-
dan, and cells were cultured until the assay. Cell growth 
assay was performed by counting cell numbers using 
a hemocytometer. Cytotoxic effects were evaluated by 
the LDH assay following the manufacturer’s protocol. 
Briefly, extracellular LDH activity in the medium was 
evaluated by an enzymatic reaction that results in forma-
zan products, which were measured with a spectropho-
tometer (Tecan Sunrise Rainbow, Tecan Japan, Tokyo) 
at 600 nm. 
siRNA transfection
Transfection of siRNA was performed with Lipo-
fectamine RNAiMAX (Invitrogen) following the manu-
facturer’s protocol. Briefly, ASK1 siRNA (sc-20748; 
Santa Cruz Biotech) was mixed with Lipofectamine 
RNAiMAX reagent in serum-free DMEM. Suspended 
cells were added to the mixture and the cell mixture was 
plated and cultured for 24 h before experimental analy-
sis.
Microarray expression analysis
Total RNA was collected from MKN45 cells using the 
RNeasy mini kit (Qiagen, Hilden, Germany). Micro-
array expression analyses were performed using the 
Agilent SurePrint G3 Human GE v2 8×60K Microarray 
(Design ID: 039494) (Agilent Technologies, Palo Alto, 
CA).
BrdU assay
BrdU assay was performed using the BrdU Cell Prolifer-
ation assay kit (Merck, Marmstadt, Germany) following 
the manufacturer’s protocol. Briefly, cells in a 96-well 
plate were cultured in medium with BrdU for 12 h. BrdU 
incorporation was detected with anti-BrdU. Signals were 
measured by spectrophotometer analysis at 450/540 nm.
Fig. 1. Effect of fucoidan on MKN45 cells. 
A:  Fucoidan impedes proliferation of MKN45 cells. The rate of MKN45 cell proliferation inhibition in the presence of increasing 
amounts of fucoidan was examined using BrdU incorporation assay. Over 5 mg/mL of fucoidan resulted in decreased BrdU incorpo-
ration. Inhibition rate was approximately 50%. 
B:  Cytotoxic effects of fucoidan in MKN45 cells. Cytotoxic effects of increasing amounts of fucoidan in MKN45 cells were examined 
by LDH assay. Cells were cultured with fucoidan as indicated for 24 h. Increasing fucoidan concentrations did not affect the rate of 
cell death, even at high doses.  
AU, arbitrary unit.  
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Western blot
Cells were lysed by sonication in 10 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
and a protease inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany) at 4 °C. Protein concentrations 
were determined with a protein assay rapid kit (Wako, 
Tokyo). Cell lysates (10 μg of protein) were separated by 
SDS-PAGE and transferred to a PVDF membrane. The 
membrane was incubated with primary antibodies at 
1:1000 dilution with TBS-Tween 20 buffer, followed by 
incubation with HRP-conjugated secondary antibody at 
1:5000 dilution. The membranes were processed using 
the ECL detection kit and images were obtained using a 
LAS-4000 image analyzer (Fujifilm, Tokyo).
Immunofluorescence staining
Cells were plated on coverslips and fixed with 3.7% 
formaldehyde in PBS for 30 min, followed by permea-
bilization in 0.1% Triton X-100 in PBS for 15 min. Cells 
were then incubated with anti-phospho-p38 antibody 
(1:200 in 0.1% BSA/PBS) for 1 h, followed by incubation 
with Alexa Fluor 488-conjugated anti-rabbit IgG for 1 
h. The coverslips were mounted with mounting medium 
containing DAPI (ProLong Gold Antifade Mounting 
with DAPI; Invitrogen), and fluorescence images were 
obtained with confocal microscopy (Leica TCS-SP2, 
Wetzler, Germany). 
  
RESULTS 
Fucoidan impedes the cell cycle
We first examined the effects of fucoidan on prolifera-
tion of MKN45 cells using the BrdU incorporation as-
say. Low doses of fucoidan had a minimal impact on 
MKN45 cell proliferation, while high doses of fucoidan, 
over 5 mg/mL, dramatically decreased BrdU incorpora-
tion. The rate of MKN45 cell proliferation inhibition by 
fucoidan was approximately 50% (Fig. 1A).
Cytotoxicity of fucoidan by LDH assay
The cytotoxic effects of treatment of MKN45 cells with 
increasing amounts of fucoidan for 24 h were examined 
by LDH assay (Fig. 1B). The results showed that 24 h 
fucoidan treatment did not induce cell death, even at 
high doses.
Clonogenic assay reveals fucoidan cytotoxic ef-
fects 
To gain fuller insight into the potential cytotoxic ef-
fects of fucoidan, we performed clonogenic assays and 
extended the incubation time to 6 days (Fig. 2A). Start-
ing at day 4, the numbers of cells were clearly reduced 
with larger doses of fucoidan. Colony formation assays 
showed similar results (Fig. 2B). We observed lower cell 
density of MNK45 cells cultured with high doses of fu-
coidan, and this reduction occurred in a dose-dependent 
manner.
 
Fig. 2. Fucoidan inhibition of MKN45 cells. 
A: Fucoidan inhibition of MKN45 cell growth. Clonogenic assays were performed by culturing MKN45 cells for 6 days in the presence 
of increasing amounts of fucoidan as indicated (F0-F20), and counting cells with a hemocytometer. Starting at day 4, the numbers of 
cells were clearly reduced with higher doses of fucoidan. 
B: Fucoidan inhibits colony formation of MKN45 cells in a dose-dependent manner. Colony formation assay of MKN45 cells incubated 
with increasing amounts of fucoidan. Cell density was lower with increasing concentrations of fucoidan. 
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Table 1. The differentially expressed G0 categories and 
gene lists in fucoidan treated MKN45 cells 
  
  
Genes that showed significant (P < 0.05) changes in upregulated or 
downregulated expression in MKN45 cells in the presence of fucoidan.  
Fig. 3. Effects of fucoidan on phosphorylation. 
A: Fucoidan downregulates cell-cycle promoting proteins. Western blot analysis revealed that over 5 mg/mL of fucoidan deceased the 
levels of phosphorylated ASK1 and phosphorylated p38 MAPK. However, the expression of ASK1 was slightly increased in a dose-
dependent manner. The expressions of p38 MAPK, ERK, and phosphorylated ERK were not changed. 
B:  Fucoidan reduces phosphorylated p38 in the nucleus. MKN45 cells were incubated with fucoidan as indicated and analyzed by im-
munofluorescence for phosphorylated p38. Treatment with fucoidan at 5 and 10 mg/mL clearly reduced the levels of phosphorylated 
p38 protein in the nucleus of MKN45 cells, which was consistent with the western blot results.
Microarray analyses of fucoidan-treated cells
To identify potential genes involved in mediating the 
cellular effects of fucoidan, total RNA was collected 
from MKN45 cells and microarray expression 
analyses were performed using the Agilent Human 
microarray kit. A total of 20278 sequences were ex-
amined at DNA Chip Research (Kanagawa, Japan), 
and 496 genes were found to be upregulated and 774 
genes were downregulated by fucoidan. Table 1 lists 
the genes in MKN45 cells with significant changes 
in expression in response to fucoidan (P < 0.05). 
Among these genes, we observed that MAP3K5, 
also known as ASK1 (apoptosis signal-regulating 
kinase), was upregulated by 1.38-fold in response to 
fucoidan. Microarray analyses accession number: 
GSE58774. 
 
Fucoidan downregulates cell cycle promoting 
proteins
From the results of the BrdU incorporation assay 
and mRNA microarray analysis, we hypothesized 
that fucoidan affected the expressions of cell cycle-
related genes. Western blot analysis revealed that 
treatment of MNK45 cells with over 5 mg/mL of 
fucoidan resulted in decreased levels of phosphory-
lated ASK1 and phosphorylated p38 MAPK. In con-
trast, the expression of ASK1 was slightly increased 
in a dose-dependent manner. The expressions of p38 
MAPK, ERK, and phosphorylated ERK were un-
changed (Fig. 3A). 
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Fig. 4. ASK1 knockdown decreases proliferation of MKN45 cells. 
A: Western blot analysis confirmed that transfection with ASK1 
siRNA reduced the expression level of ASK1 protein com-
pared with control cells. Beta-tubulin was used as an internal 
control. 
B: To examine the effect of ASK1 suppression on proliferation 
of MKN45 cells, ASK1 siRNA was transfected into MKN45 
cells and Brdu assay was performed. Genetic inhibition of 
ASK1 repressed the proliferative activity of MKN45 cells.  
AU, arbitrary unit.   
 We also performed fluorescence immunostaining 
of MNK45 cells with phosphorylated p38 antibody and 
found that 5 and 10 mg/mL fucoidan treatment clearly 
reduced phosphorylated p38 protein levels in the nucleus 
(Fig. 3B), which was consistent with the western blot 
results. These results suggested the possibility that fucoi-
dan inhibited proliferation of MKN45 cells by suppress-
ing the ASK1-p38 signaling pathway.
ASK1 knockdown reduces proliferation of MKN45 
cells
To examine the effect of ASK1 suppression on MKN45 
cell proliferation, ASK1 siRNA was transfected into 
MKN45 cells. Western blot analyses confirmed that 
ASK1 siRNA reduced ASK1 protein levels compared 
with control cells (Fig. 4A). BrdU assay revealed that 
genetic inhibition of ASK1 repressed MKN45 cell prolif-
eration (Fig. 4B).
DISCUSSION
Recent studies have shown that marine bioactive com-
pounds can either modulate signaling pathways leading 
to cell cycle regulation or directly alter cell cycle regula-
tory molecules in cancer therapy. The anti-proliferative 
activity of fucoidan may be a result of its interference in 
cell cycle progression.
 Previous studies demonstrated that fucoidan caused 
a cell cycle arrest at the G0/G1 phase in hepatocarci-
noma cell lines18 and suppressed cell proliferation and 
arrested the cell cycle in hepatocellular carcinoma cell 
lines.19 Our BrdU results showed that cell proliferation 
was suppressed at a dose of fucoidan of over 5 mg/mL 
in 24 h, which impeded DNA synthesis and cell pro-
liferation during S phase in MKN45 cells. This result 
demonstrated that fucoidan induced cell cycle arrest in 
MKN45 cells.
 We explored the cytotoxic effects of fucoidan in 
MKN45 cells by LDH assay. After 24 h of incubation, fu-
coidan-treated MKN45 cells did not exhibit any elevation 
in LDH release compared with the control group, even at 
high doses (Fig. 1B). This result was consistent with pre-
vious studies.18, 19 However, other studies demonstrated 
cytotoxicity of fucoidan in different cancer cells.19, 20
 These discrepancies in cytotoxicity among fucoi-
dans are likely due to variations in fucoidan polymer 
structure and function, as fucoidans originate from 
various species, anatomical regions, and under different 
growing conditions of brown seaweeds. Fucoidans are 
also subject to specific extraction and purification pro-
cedures. Furthermore, fucoidans may also exhibit cell-
type-specific effects, with different functions in different 
cancer cell lines. Additionally, even though cell prolif-
eration was repressed by fucoidan in previous reports, 
the repression was not evident at 24 h by MTT assay.19 
We also did not observe cytotoxic effects of fucoidan at 
24 h. We speculated that a longer time course may better 
reveal fucoidan effects under long exposure conditions, 
and subsequently extended the incubation time to 6 days. 
Under longer treatment conditions, we observed both a 
marked decrease in cell number and reduction of cell 
density in a dose-dependent manner. 
 We performed mRNA microarray analysis to iden-
tify potential gene targets of fucoidan in mediating its 
cell cycle effects. MAP3K5 or ASK1 that was identified 
as a MAPK kinase kinase, was upregulated 1.38-fold 
in response to fucoidan. ASK1 is involved in regulating 
the cell cycle and is phosphorylated at the beginning of 
S phase.21 This suggested that phosphorylation might 
facilitate ASK1’s function in the spindle-kinetochore 
interaction, which presumably occurs during the S phase 
after the duplication of kinetochores. This also implies 
that decreasing phosphorylated ASK1 would impair the 
cell cycle during S phase. 
 In the MAPK pathway, p38 MAPK functions as a 
downstream kinase of ASK1. p38 MAPK was reported 
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to promote cancer cell growth and survival.22 In a study 
investigating the effect of fucoidan on lung carcinoma, 
fucoidan treatment resulted in decreased phospho-p38 
levels,23 which demonstrated anti-cancer effect due to 
fucoidan.
 Another MAPK, ERKs are known to promote 
cell survival, differentiation, cell proliferation24 and 
cell death.25 A previous study showed fucoidan clearly 
decreased the phosphorylation of ERK in HS-Sultan 
cells.26
 In evaluating the results of the mRNA microar-
ray analysis, we therefore focused on genes involved in 
cell cycle regulation to examine potential mediators of 
fucoidan. Based on the BrdU incorporation results, we 
hypothesized that the protein levels of ASK1 and its 
related proteins would be altered by fucoidan, and we 
performed western blot analysis of ASK1, p38 MAPK, 
and ERK steady state and phosphorylated forms to de-
termine the effects of fucoidan.
 Treatment with over 5 mg/mL fucoidan effectively 
deceased phosphorylated ASK1 and phosphorylated 
p38 MAPK levels, while ERK expression remained 
unchanged. The western blot results furthered the BrdU 
incorporation findings, suggesting that fucoidan caused 
reduction of phosphorylated ASK1 expression, arresting 
the cell cycle in S phase and eventually impairing DNA 
synthesis. This results in damaging proliferation of can-
cer cells. 
 Consistent with the microarray analysis, fucoidan 
increased ASK1 protein levels. Increased ASK1 protein 
could possibly result from a reduction of phosphorylated 
ASK1 by fucoidan. As a consequence of reduced phos-
phorylated ASK1, the mRNA levels were compensatory 
amplified, resulting in increased expression of ASK1. 
 A previous study demonstrated elevation of ASK1 in 
human gastric cancer and showed that overexpression of 
ASK1 promoted gastric cancer cell proliferation.27 An-
other report found that ASK1 inhibition prevents gastric 
cancer cell growth in vitro and in vivo.28 This mecha-
nism involved cyclin D, a known regulator of the G1 to 
S phase transition.29 However, this mechanism seemed 
specific to gastric cancer cells, as ASK1 knockdown 
in other cell lines did not inhibit proliferation.28 The 
previous study supports the results of the current study, 
demonstrating that genetic inhibition of ASK1 repressed 
MKN45 cell proliferation.
 To elucidate the mechanisms underlying the anti-
cancer activities of fucoidan, determining its binding 
partners and targets would help clarify its activities. One 
study reported that fucoidan acts as a polysaccharide 
ligand of P-selectin, with nanomolar affinity.30 P-selectin 
is an adhesion molecule expressed at the surface of en-
dothelial cells and platelets on activation. P-selectin pro-
motes platelet, endothelium, and leukocyte interactions, 
and was reported to cause cardiovascular events.31
 Fucoidan exhibited the highest affinity for P-
selectin32 and repressed its function in platelet aggrega-
tion.31 This implied that fucoidan targets the surface 
of endothelial cells, with potential consequences on 
downstream signal transduction pathways. Our findings 
show that fucoidan induces alterations of gene expres-
sion, which may possibly involve its function at the cell 
surface.
 In conclusion, our study indicated that fucoidan may 
suppress cellular proliferation and DNA synthesis in 
MKN45 cells by suppressing the ASK1-p38 signaling 
pathway through a reduction in phosphorylated ASK1 
levels. Our findings strongly suggest fucoidan as a po-
tential therapeutic agent for cancer therapies. Further 
investigations would provide new approaches to the de-
velopment of effective chemotherapy regimens. 
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